Lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) therapies represent a fundamentally different strategy for generating chimeric antigen receptor (CAR)-expressing immune cells. Rather than relying on viral transduction or ex vivo cell manufacturing, this approach delivers mRNA encoding a CAR construct directly via targeted LNPs, enabling transient, controllable CAR expression in vivo. The result is a therapy that sidesteps the logistical burden and scalability constraints of autologous cell manufacturing while retaining the ability to redirect immune effector function against defined tumor-associated antigens.
Building a viable candidate in this space demands simultaneous mastery of multiple disciplines: mRNA construct engineering, multi-specific binder design, lipid formulation science, surface-conjugation chemistry for cell-targeted delivery, and functional immunology to confirm that the transiently expressed CAR drives meaningful anti-tumor activity. Ace Therapeutics has assembled a dedicated platform that integrates these capabilities into a single, coordinated workflow — from construct architecture through in vivo proof-of-concept — so that sponsors can advance LNP-mRNA CAR candidates without fragmenting their programs across disconnected vendors.
Built as a suite of six synergistic modules, the LNP-Delivered Multi-Specific CAR mRNA Engineering Platform is designed to streamline the preclinical development of in vivo LNP-mRNA CAR therapeutics:
This module addresses the molecular architecture of the CAR itself — defining the arrangement of antigen-binding domains, hinge and transmembrane segments, co-stimulatory motifs, and signaling domains to achieve optimal surface expression and functional potency upon mRNA translation. For multi-specific designs incorporating tandem single-chain variable fragments (scFvs) directed against two or more tumor antigens, particular attention is given to domain orientation, linker geometry, and the impact of construct length on translational efficiency. The mRNA backbone is then optimized — including 5ʹ cap structure, untranslated region selection, codon usage, and modified nucleotide incorporation — to maximize protein output and minimize innate immune activation. Clients receive a fully characterized, in vitro-validated mRNA construct ready for encapsulation.
LNP composition directly governs encapsulation efficiency, particle stability, cellular uptake, and endosomal escape — each of which determines how much functional mRNA reaches the cytoplasm of the target cell. This module covers the rational selection and proportioning of ionizable lipids, phospholipids, cholesterol, and PEGylated lipid components, followed by microfluidic or rapid-mixing assembly at bench and scalable formats. Formulation parameters are systematically screened and refined using design-of-experiment approaches, with characterization outputs including particle size distribution, zeta potential, encapsulation efficiency, and mRNA integrity post-encapsulation. The deliverable is a reproducible LNP formulation protocol paired with stability and release data.
Achieving cell-type-selective delivery of mRNA cargo requires decorating the LNP surface with targeting ligands — most commonly antibodies or antibody fragments — via bioorthogonal click chemistry. This module provides end-to-end support for the conjugation workflow: functionalization of PEGylated lipid termini with reactive handles, site-selective modification of targeting antibodies with complementary reactive groups, and controlled coupling under conditions that preserve both LNP colloidal stability and antibody binding activity. Conjugation efficiency, ligand density, and retention of targeting function are quantified for each batch. Sponsors receive a surface-engineered, targeted LNP ready for biological evaluation.
Before advancing to animal studies, the candidate must demonstrate that its mRNA cargo is efficiently translated in relevant cell types and that the resulting CAR protein is correctly trafficked, surface-displayed, and functionally competent. This module provides transfection and expression analysis in primary human immune cells and representative cell lines, using flow cytometry (including reporter-based tracking), Western blot, and confocal microscopy. Functional readouts include target-cell binding, immune synapse formation, cytokine secretion profiling, and cytotoxicity assays against antigen-positive tumor cell panels. The output is a comprehensive in vitro data package characterizing expression kinetics, CAR surface density, and effector function.
Translating in vitro performance into in vivo anti-tumor activity requires pharmacology models that recapitulate the relevant disease biology. This module supports the design and execution of efficacy studies in tumor-bearing mouse models — including xenograft, syngeneic, and patient-derived xenograft formats — with endpoints encompassing tumor volume, survival, immune cell infiltration, and target-cell depletion. Parallel biodistribution studies using reporter-based or molecular tracking methods quantify LNP tropism, off-target organ accumulation, and the duration of CAR expression across tissues. Pharmacokinetic sampling provides data on mRNA and LNP clearance. Sponsors receive a preclinical efficacy and distribution dataset suitable for candidate selection and IND-enabling study design.
Transient CAR expression from mRNA offers intrinsic safety advantages over permanent genomic integration, but LNP-mRNA therapies introduce their own risk profile — including complement activation-related pseudoallergy, cytokine release, anti-PEG immunity, and potential off-target immune stimulation. This module evaluates these risks through cytokine storm modeling, repeated-dose tolerability studies, anti-drug antibody assays, complement activation panels, and histopathological analysis of key organs. Immunogenicity of both the LNP carrier and the encoded CAR protein is assessed longitudinally. The deliverable is a translational safety dossier that maps the candidate's risk profile and informs clinical dose-escalation strategy.
Unified multi-disciplinary execution. LNP-mRNA CAR programs span molecular biology, formulation science, bioconjugation chemistry, immunology, and in vivo pharmacology. Fragmenting these across multiple contract research organizations introduces handoff delays, data format inconsistencies, and accountability gaps. This platform houses every required discipline under a single project management framework, ensuring that upstream design decisions are informed by downstream functional and safety requirements from day one.
Construct-to-formulation co-optimization. mRNA construct features (length, secondary structure, modified nucleotide content) interact directly with LNP encapsulation behavior and translational output. Because construct engineering and formulation development are conducted by integrated teams sharing real-time data, this platform enables iterative co-optimization — adjusting mRNA design to improve encapsulation, or reformulating to accommodate a construct change — rather than treating these as independent, sequential steps.
Validated surface-engineering chemistry. Decorating LNPs with targeting antibodies without compromising particle integrity or ligand function is technically demanding and poorly standardized. This platform employs a mature bioorthogonal conjugation workflow with established quality controls for coupling efficiency, ligand orientation, and batch-to-batch reproducibility, reducing the risk that targeting performance observed in screening fails to translate into production batches.
Transient expression pharmacology expertise. The kinetics of mRNA-driven CAR expression — rapid onset, defined duration, and clearance without genomic integration — create a pharmacological profile distinct from viral CAR T therapies. The in vivo study designs used by this platform are specifically calibrated for these kinetics, including optimized dosing schedules, time-resolved expression monitoring, and re-dosing paradigms that conventional CAR T efficacy models do not adequately address.
Safety-first translational framework. LNP-associated immunotoxicities (complement activation, anti-PEG responses, innate immune stimulation) are among the most common reasons for clinical holds in the mRNA therapeutic space. By embedding dedicated immunogenicity and safety modules into every program — not as optional add-ons but as standard workflow elements — the platform generates the risk characterization data that regulatory agencies expect, reducing the likelihood of late-stage surprises.
GQQ6-944 is an mRNA therapeutic encoding a second-generation CAR construct with tandem scFv domains directed against two distinct surface antigens expressed on malignant plasma cells and related hematologic tumor populations: SLAM family member 7 (SLAMF7) and TNF receptor superfamily member 17 (TNFRSF17, also known as BCMA). The CAR architecture incorporates a CD8α hinge and transmembrane domain, a 4-1BB co-stimulatory intracellular domain, a CD3ζ signaling domain, and an enhanced green fluorescent protein (EGFP) reporter for expression tracking. The mRNA is encapsulated within LNPs composed of an ionizable lipid, phosphatidylcholine, a PEGylated lipid bearing a reactive azide moiety, and cholesterol. The LNP surface is subsequently functionalized with antibodies via strain-promoted click chemistry to enable cell-type-targeted delivery.
This dual-targeting strategy is designed to counteract antigen escape — a well-documented resistance mechanism in hematologic malignancies treated with single-antigen-directed therapies — by simultaneously engaging two independent surface markers. Delivering the CAR as mRNA rather than via viral vector offers transient, titratable expression that may reduce the risk of prolonged on-target off-tumor toxicity while enabling repeated dosing to sustain therapeutic pressure.
GQQ6-944 is being evaluated for lymphocytic leukemia and multiple myeloma, indications where both SLAMF7 and BCMA are broadly expressed on malignant cells and represent validated therapeutic targets.
| Candidate | Target | Indication | Modality |
|---|---|---|---|
| GQQ6-944 | SLAMF7; TNFRSF17 (BCMA) | Lymphocytic leukemia; Multiple myeloma | Lipid nanoparticle-formulated mRNA therapy |
Developing an LNP-delivered mRNA therapy encoding a multi-specific CAR against SLAMF7 and TNFRSF17 combines the engineering complexity of bispecific immunotherapy with the formulation and delivery challenges of non-viral mRNA therapeutics. Each target has distinct expression patterns across normal and malignant tissues, and the simultaneous engagement of both requires careful balancing of binding affinity, construct architecture, and in vivo delivery kinetics. Below, we outline the principal development challenges and the platform-specific approaches that address them.
Incorporating two scFv domains in tandem within a single CAR construct introduces folding and steric constraints. The relative positioning, linker length, and domain orientation of the anti-SLAMF7 and anti-TNFRSF17 scFvs profoundly affect whether both binding sites remain accessible on the cell surface, whether the construct folds correctly during co-translational membrane insertion, and whether the overall protein remains within the size constraints compatible with efficient mRNA translation.
Platform Solution: Module 1 employs a systematic domain-shuffling and linker-optimization strategy, generating a focused library of tandem CAR variants that are rapidly screened for surface expression level, dual-antigen binding by flow cytometry, and functional cytotoxicity against single-positive and double-positive target cell lines. This empirical screening, coupled with structural modeling of scFv pairing and hinge geometry, identifies lead architectures that achieve balanced engagement of both antigens without sacrificing expression efficiency.
Multi-specific CAR constructs — particularly those incorporating reporter tags such as EGFP — produce long mRNA transcripts that are more susceptible to degradation during formulation, storage, and intracellular processing. Longer mRNAs also translate less efficiently on a per-molecule basis, requiring higher delivered doses that may amplify LNP-related toxicities.
Platform Solution: Module 1 and Module 2 work in concert to address this challenge. On the mRNA side, codon optimization algorithms are applied with explicit penalties for secondary structures that impede ribosomal processivity across the full-length open reading frame. Untranslated region elements are selected from high-expression genetic contexts to maximize ribosomal recruitment. On the formulation side, LNP assembly conditions (mixing speed, buffer pH, lipid-to-mRNA ratio) are optimized specifically for long mRNA payloads, with mRNA integrity monitored by capillary electrophoresis at each process step. The result is a formulated product that preserves full-length transcript integrity above predefined thresholds.
Systemically administered LNPs exhibit a strong natural tropism for hepatocytes, driven by apolipoprotein adsorption and receptor-mediated uptake in the liver. For a CAR mRNA therapy, productive delivery must occur in immune effector cells — not hepatocytes — making active targeting essential. However, conjugating antibodies to the LNP surface must not disrupt colloidal stability, alter biodistribution in unintended ways, or trigger accelerated clearance via Fc receptor-mediated uptake.
Platform Solution: Module 3 provides a bioorthogonal surface-engineering workflow that couples targeting antibodies to azide-functionalized PEG-lipid termini via strain-promoted cycloaddition. This chemistry proceeds under mild, aqueous conditions without catalysts, preserving both LNP integrity and antibody function. Ligand density is titrated to identify the window that maximizes target-cell uptake while minimizing non-specific liver sequestration. Fc engineering or fragment-based targeting formats are available to mitigate unwanted Fc receptor interactions. Biodistribution studies in Module 5 provide quantitative confirmation that the targeted LNP redirects mRNA delivery away from the liver and toward the intended immune cell compartment.
Unlike virally transduced CAR T cells that express the receptor permanently, mRNA-driven CAR expression is inherently transient — typically peaking within hours and declining over days. This kinetic profile complicates efficacy modeling: standard CAR T xenograft protocols, which track tumor regression over weeks following a single cell infusion, are poorly suited to a modality that may require repeated dosing to sustain anti-tumor pressure. Additionally, for dual-targeted therapies against SLAMF7 and TNFRSF17, animal models must express both antigens on tumor cells in a biologically relevant pattern.
Platform Solution: Module 5 deploys customized pharmacology study designs that account for transient expression kinetics. Dosing schedules are built around time-resolved expression monitoring (using the EGFP reporter or equivalent tracking approach) to define the therapeutic window and inform re-dosing intervals. Tumor models are selected or engineered to co-express both SLAMF7 and TNFRSF17 at clinically relevant densities, enabling assessment of dual-targeting benefit over single-target controls. Efficacy endpoints include not only tumor volume and survival but also serial measurement of residual tumor antigen expression to detect early signs of antigen escape under therapeutic pressure.
A key advantage of mRNA-based delivery — the ability to re-dose — introduces a corresponding challenge: repeated LNP administration can trigger anti-PEG antibodies, complement activation-related pseudoallergy, and escalating innate immune responses that reduce efficacy and increase toxicity with each subsequent dose. These phenomena are well documented for PEGylated nanoparticles and represent a material translational risk for any LNP-mRNA program designed around a multi-dose regimen.
Platform Solution: Module 6 systematically characterizes these risks across single-dose and repeat-dose scenarios. Anti-PEG IgM and IgG are tracked longitudinally by ELISA. Complement activation is assessed via C3a, C5a, and sC5b-9 quantification following each dose. Cytokine panels (including IL-6, TNF-α, IFN-α, and IL-1β) are measured at serial time points to map the innate immune response signature. Where anti-PEG immunity is observed, the platform can evaluate mitigation strategies including PEG-lipid alternatives, dose interval optimization, and transient immunomodulation protocols. This iterative safety characterization directly informs the clinical dosing strategy and risk management plan.
SLAMF7 and TNFRSF17 are expressed on normal immune cell subsets — SLAMF7 on natural killer cells, activated T cells, and plasmacytoid dendritic cells; TNFRSF17 on mature plasma cells. A CAR simultaneously targeting both antigens carries an inherent risk of depleting normal cell populations that are critical for immune defense and humoral immunity. Quantifying this risk preclinically requires models and assays that can distinguish tumor-directed cytotoxicity from bystander immune cell depletion.
Platform Solution: The platform addresses this through paired in vitro and in vivo approaches. Module 4 includes mixed co-culture assays that combine antigen-positive tumor cells with normal human peripheral blood mononuclear cells, measuring selective versus non-selective killing by flow cytometric enumeration of each population. Module 5 in vivo studies incorporate serial immunophenotyping of normal immune compartments — including NK cells, T cell subsets, and plasma cell frequencies — alongside tumor response monitoring. The transient nature of mRNA-driven CAR expression provides an inherent safety buffer, as off-tumor effects are time-limited. Duration-of-depletion and immune recovery kinetics are explicitly characterized to define the therapeutic index and inform clinical risk-benefit assessment.
Ace Therapeutics boasts a team of highly committed and skilled researchers dedicated to delivering innovative preclinical contract research solutions.
We provide tailored preclinical services designed to streamline your research process and advance promising concepts into actionable insights, ensuring efficient progress in drug development.
Copyright © Ace Therapeutics. All rights reserved.
↑